Physician profile
David C Napier
NPI 1083639272
$771.74
in general payments reported to CMS, 2019-2025
15 companies · $364 in 2025
The $364 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.93 · 2020: $59.61 · 2021: $181 · 2022: $32.01 · 2024: $89.71 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $453.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $205.90 | 2021-2025 | Shingrix |
| Abbvie INC. | $123.38 | 2021-2025 | |
| Pfizer INC. | $92.06 | 2019-2025 | |
| Novo Nordisk INC | $92.01 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $55.01 | 2020-2025 | Otezla, Repatha |
| Medtronic, INC. | $52.12 | 2022-2025 | Minimed 780g |
| Merck Sharp & Dohme LLC | $24.22 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.03 | 2025 | |
| Axsome Therapeutics, INC. | $19.85 | 2025 | Auvelity |
| Insulet Corporation | $18.33 | 2025 | Omnipod |
| Seqirus USA INC | $17.82 | 2024 | Fluad, Flucelvax |
| Inspire Medical Systems, INC. | $16.18 | 2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $16.03 | 2025 | Farxiga |
| Vital Connect, INC | $14.23 | 2025 | Vitalpatch Rtm |
| Phathom Pharmaceuticals, INC. | $4.57 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Napier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.